ATE401395T1 - Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren - Google Patents

Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren

Info

Publication number
ATE401395T1
ATE401395T1 AT02769340T AT02769340T ATE401395T1 AT E401395 T1 ATE401395 T1 AT E401395T1 AT 02769340 T AT02769340 T AT 02769340T AT 02769340 T AT02769340 T AT 02769340T AT E401395 T1 ATE401395 T1 AT E401395T1
Authority
AT
Austria
Prior art keywords
disorders
diseases
psychiatric
deacetylase inhibitors
treating neurodegenerative
Prior art date
Application number
AT02769340T
Other languages
English (en)
Inventor
Joan Steffan
Leslie Thompson
J Marsh
Laszlo Bodai
Judit Pallos
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE401395T1 publication Critical patent/ATE401395T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60New or modified breeds of invertebrates
    • A01K67/61Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65Genetically modified arthropods
    • A01K67/68Genetically modified insects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
AT02769340T 2001-05-02 2002-05-02 Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren ATE401395T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28821501P 2001-05-02 2001-05-02
US37272402P 2002-04-11 2002-04-11

Publications (1)

Publication Number Publication Date
ATE401395T1 true ATE401395T1 (de) 2008-08-15

Family

ID=26964894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769340T ATE401395T1 (de) 2001-05-02 2002-05-02 Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren

Country Status (5)

Country Link
EP (1) EP1390491B1 (de)
AT (1) ATE401395T1 (de)
DE (1) DE60227658D1 (de)
ES (1) ES2310213T3 (de)
WO (1) WO2002090534A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
CA2463552C (en) 2001-10-16 2011-05-17 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2502649A1 (de) 2005-02-03 2012-09-26 TopoTarget UK Limited Kombinationstherapie mit HDAC-Hemmern und Erlotinib zur Behandlung von Krebs
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
GB0518235D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2009507081A (ja) * 2005-09-07 2009-02-19 ブレインセルス,インコーポレイティド HDac阻害による神経発生の調整
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5163986B2 (ja) * 2005-09-23 2013-03-13 エスケー バイオファーマスティカルズ カンパニー リミテッド フェニル酪酸ナトリウムを使用する、薬物依存症又はアルコール依存症或いは躁うつ病の予防又は治療のための医薬組成物
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
JP2010514801A (ja) 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ, インコーポレイテッド ロミデプシンの精製
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP3524324A1 (de) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Histondeacetylaseinhibitoren
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2599479A1 (de) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure zur Behandlung der Alzheimer-Krankheit
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN103861084A (zh) * 2014-02-12 2014-06-18 新乡医学院 Romidepsin在治疗帕金森病中的应用
US9655910B2 (en) 2014-03-21 2017-05-23 Bodybio Inc. Compositions and methods for treating addiction
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
EP3383494A4 (de) * 2015-12-04 2019-08-07 The Regents of The University of California Histondeacetylase-inhibitoren
KR20220070465A (ko) 2019-09-27 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 Hdac6 억제제로서 유용한 2-이소인돌-1,3,4-옥사디아졸 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Also Published As

Publication number Publication date
EP1390491B1 (de) 2008-07-16
ES2310213T3 (es) 2009-01-01
DE60227658D1 (de) 2008-08-28
EP1390491A1 (de) 2004-02-25
EP1390491A4 (de) 2005-04-06
WO2002090534A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
ATE401395T1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
MY132784A (en) "prevention and treatment of amyloidogenic disease"
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60325717D1 (de) Verfahren zur behandlung von angststörungen bei älteren personen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60210614D1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
DK1343472T3 (da) Thixotropisk næsespray
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE513471T1 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390491

Country of ref document: EP